Lassauniere 2020 [E].

Study characteristics
Patient Sampling	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Patient characteristics and setting	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Index tests	9 tests evaluated, 3 ELISA and 6 LFIA; this entry ( Lassauniere 2020 [E] ) refers to test [E] [E] Test name: OnSiteTM COVID‐19 IgG/IgM Rapid Test Manufacturer: CTK Biotech, Poway, CA, USA; Cat # R0180C Ab targets: IgM, IgG Antigens used: NR Test method: CGIA Timing of samples: Samples used: serum Test operators: laboratory staff Definition of test positivity: visible line Blinded to reference standard: no Threshold predefined: yes
Target condition and reference standard(s)	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Flow and timing	See main entry for this study for characteristics and QUADAS‐2 assessment ( Lassauniere 2020 [A] )
Comparative
Notes